GB985206A — Improvements in or relating to therapeutic iron preparation

USPTO Abstract

A polymeric g -ferric oxide-hydroxide of formula (g -FeOOH)n is said to be formed in the preparation of a ferric hydroxide-polyisomaltose complex. An aqueous solution of an alkali metal carbonate or bicarbonate is added to an aqueous solution of polyisomaltose and an iron salt at 15-25 DEG C., to give a pH of about 2.6. Alkali metal hydroxide is then added to form a suspension of pH 11 or more, and the suspension is heated to form a solution.ALSO:A ferric hydroxide-polyisomaltose (i.e. water-soluble dextran) complex comprises 2 mols. of iron per anhydroglucose unit. The complex, which contains about 33% of iron, is made by adding to an acidic solution of polyisomaltose and a water-soluble iron compound at 15 DEG to 25 DEG C., an aqueous solution of an alkali metal carbonate or bicarbonate, subsequently adding an alkali metal hydroxide, heating the resulting suspension to form a solution and neutralizing the solution. Specified iron compounds are ferric chloride, acetate, sulphate or nitrate. The solution of the complex may be neutralized, e.g. addition of acids or ion-exchange resins. Electrolytes may be removed by further addition of ion-exchange resins or by dialysis, and the complex may be isolated by precipitation with organic solvents or by evaporation of the solution. The viscosity of the polyisomaltose may be reduced, if necessary, by heating and subsequently cooling the acids olution of iron compound and polyisomaltose. Preferably, alkali metal carbonate or bicarbonate is added to give a pH of about 2.6, and alkali metal hydroxide to give a suspension of pH not less than 11. The suspension may be heated to e.g. 90-100 DEG C. The polysaccharide is said to complex with a polymeric g -ferric oxide-hydroxide (g -FeOOH)n (Division C1). The complex is non-colloidal, and has therapeutic properties (Division A5). Specifications 748,024, Canadian Specifications 623,411, 623,412 and U.S.A. Specification 2,885,393 are referred to.ALSO:A parenterally-injectable composition for the treatment of iron-deficiency anaemia contains an iron hydroxide-polyisomaltose (a water-soluble dextran) complex comprising 2 moles of iron per anhydroglucose unit and containing about 33% by weight of iron. Specification 748,024 is referred to.